Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

NCT03104725 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT03104725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03104725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 1
Overall status
Terminated
Start date
September 25, 2017
Completion date
February 27, 2020
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrospinal fluid, parkinson disease